📷 Image: Wikimedia Commons / Vimal Rajyaguru
Business
FDA Receives Responses from All Parties in Vimal Elaichi Ad Dispute; Hearings Wrap Up in Two Cases
✍️ StoryBoard 18
🗓 01 Oct 2026, 04:47 AM
👁 7
The Food and Drug Administration has received replies from all three parties involved in the Vimal Elaichi advertisement controversy, and hearings have concluded in two of the cases.
The Food and Drug Administration (FDA) has officially received responses from all three parties involved in the Vimal Elaichi advertisement controversy. The agency had earlier called for a formal hearing to examine the claims that the spice brand’s commercial contained misleading statements.
During the proceedings, the FDA reviewed submissions from the brand’s marketing team, the consumer advocacy group that lodged the complaint, and a third party representing the advertising agency. All parties provided written replies, which the FDA has now incorporated into its final assessment.
The agency announced that hearings in two of the three cases have been concluded. In both instances, the FDA found no substantial evidence of false or deceptive claims in the advertisement. The third case remains under review, with the FDA scheduled to issue a decision in the coming weeks.
The Vimal Elaichi ad row has attracted significant media attention, prompting the FDA to emphasize its commitment to ensuring that food product advertisements comply with national regulations. The agency has urged brands to maintain transparency and accuracy in their promotional materials.
Consumers who have raised concerns can now expect a formal resolution from the FDA, which will outline any corrective actions required from the brand or its advertising partners.
During the proceedings, the FDA reviewed submissions from the brand’s marketing team, the consumer advocacy group that lodged the complaint, and a third party representing the advertising agency. All parties provided written replies, which the FDA has now incorporated into its final assessment.
The agency announced that hearings in two of the three cases have been concluded. In both instances, the FDA found no substantial evidence of false or deceptive claims in the advertisement. The third case remains under review, with the FDA scheduled to issue a decision in the coming weeks.
The Vimal Elaichi ad row has attracted significant media attention, prompting the FDA to emphasize its commitment to ensuring that food product advertisements comply with national regulations. The agency has urged brands to maintain transparency and accuracy in their promotional materials.
Consumers who have raised concerns can now expect a formal resolution from the FDA, which will outline any corrective actions required from the brand or its advertising partners.